Board of Directors

Jonathan S. Wolfson Chief Executive Officer

Jonathan Wolfson Jonathan S. Wolfson is a co-founder and was our President and Chief Operating Officer from 2003 until 2008 when he became Chief Executive Officer. Prior to founding Solazyme, Mr. Wolfson held a variety of positions in finance, business and law, most recently that of Vice President of Finance and Business Development for 7thOnline, Inc., a supply chain software company. Immediately prior to that Mr. Wolfson was co-founder and Chief Operating Officer of InvestorTree, Inc., a financial services software company. Mr. Wolfson obtained a law degree from New York University (NYU) School of Law and an M.B.A. from NYU Stern School of Business. He has served as a member of our board of directors since inception. Mr. Wolfson is a valuable member of the board of directors due to his leadership, his experience in finance and business and his extensive understanding of the company, which brings historic knowledge and continuity to the board of directors.

Harrison F. Dillon, Ph.D. President

Harrison Dillon

Harrison F. Dillon is a co-founder and President of Solazyme. Prior to founding Solazyme, Dr. Dillon was an associate at Kilpatrick Townsend & Stockton LLP formerly Townsend and Crew LLP, a law firm, from 2003 to 2004. Prior to joining Kilpatrick Townsend & Stockton LLP, Dr. Dillon held a variety of positions related to intellectual property law and technology licensing at Parsons, Behle, and Latimer PLC, a law firm, and the University of Utah Research Foundation, an academic institution. Dr. Dillon obtained a J.D. from Duke University School of Law and a Ph.D. in genetics from the University of Utah. He has served as a member of our board of directors since inception. Dr. Dillon is a valuable member of the board of directors due to his leadership, his extensive knowledge of intellectual property and his extensive understanding of the company, which brings historic knowledge and continuity to the board of directors.



Michael V. Arbige, Ph.D.

Michael V. Arbige has been a member of our board of directors since 2005. From 1990 to the present, Dr. Arbige has held a variety of positions at Genencor, a division of Danisco US Inc., a diversified biotechnology company, and is currently its Executive Vice President of Research and Development, Dr. Arbige has held this position since 1999. He is responsible for all activities associated with managing and driving the research and development activities for the company. Dr. Arbige obtained his Ph.D. in Microbial Physiology and Genetics in 1982 from the University of New Hampshire. Dr. Arbige is a valuable member of the board of directors due to his experience in and knowledge of the biotechnology sector.

Ian T. Clark

Ian T. Clark has been a member of our board of directors since April 2011. Mr. Clark is currently the chief executive officer and head of North American commercial operations at Genentech, a wholly-owned member of the Roche Group. From 2009 to 2010, he was a member of the board of directors of Dendreon Corporation and served on its Corporate Governance Committee. Prior to January 2010, he was head of global product strategy and chief marketing officer at Roche, Pharma Division since March 2009. Mr. Clark previously was executive vice president of commercial operations since 2006, senior vice president of commercial operations since 2005, and senior vice president of oncology commercial operations for Genentech's BioOncology business unit since 2003, which focused on global commercialization of the company's diverse oncology pipeline, including Avastin ® , Rituxan ® and Herceptin ® . Prior to his time at Genentech, Mr. Clark was president of Novartis Canada from 2001 to 2003 and chief operating officer of Novartis United Kingdom from 1999 to 2001, and also served on the Board of Directors of Vernalis, a pharmaceutical company, from 2007 to 2009. Mr. Clark received a B.S. in biological sciences from Southampton University in the United Kingdom. Mr. Clark is a valuable member of the board of directors due to his experience in and knowledge of the biotechnology sector and his leadership experience.

Jerry Fiddler

Jerry Fiddler has been a member and the chairman of our board of directors since 2004. From 1981 to 2009 Mr. Fiddler was, at various times, the founder, Chief Executive Officer, Chairman and/or director of Wind River Systems, Inc., a publicly held software company, until it was acquired by Intel Corporation, a semiconductor company. Mr. Fiddler is the principal/CEO of Zygote Ventures, LLC, and an adjunct professor at University of California, Berkeley. He serves on a number of private company and non-profit boards. Mr. Fiddler obtained an M.S. from the University of Illinois. Mr. Fiddler is a valuable member of the board of directors due to his 97 and corporate governance experience, his experience as CEO and chairman of a public company, his service on the boards of directors of other private companies and non-profit entities and his extensive knowledge of the company due to his service on the board of directors since 2004, which brings historic understanding and continuity to the board of directors.

William D. Lese

William D. Lese has been a member of our board of directors since 2008. Mr. Lese co-founded and since 2002 has served as a managing partner of Braemar Energy Ventures, LP, a venture capital management company, focused exclusively on investing in early to mid-stage energy technology companies predominantly located in the United States and Canada. Mr. Lese holds a B.A. in Physics and a M.Sc. in Energy Sciences from New York University. Mr. Lese is a valuable member of the board of directors due to his experience in and knowledge of the technology sector and his knowledge of energy and environmental businesses.

Ann Mather

Ann Mather has been a member of our board of directors since April 2011. Ms. Mather has also been a member of the board of directors of: Google Inc., an online search provider, since November 2005, and serves as chair of its Audit Committee; MGM Holdings Inc., a motion picture and television production and distribution company, since December 2010, and serves on its Compensation Committee; MoneyGram International, a global payment services company, since May 2010; and Netflix, Inc., an internet subscription service for movies and television shows, since July 2010, and serves on its Audit Committee. She also serves as a board member to Glu Mobile Inc., a publisher of mobile games, since September 2005, and formerly served as chair of its Audit Committee. Ann has also been an independent trustee to the Dodge & Cox Funds board of trustees since May 2011. Ann was previously a director of Central European Media Enterprises Group, a developer and operator of national commercial television channels and stations in Central and Eastern Europe, from 2004 to 2009. From 1999 to 2004, Ann was Executive Vice President and Chief Financial Officer of Pixar, a computer animation studio. Prior to her service at Pixar, Ann was Executive Vice President and Chief Financial Officer at Village Roadshow Pictures, the film production division of Village Roadshow Limited. Ann holds a Master of Arts degree from Cambridge University in England and is a chartered accountant.


Board Structure

Our board of directors currently consists of eight members, comprised of six non-employee members and our president and chief executive officer. Each director serves until the next meeting of stockholders and until their successors are duly elected and qualified. Mr. Fiddler serves as the Chairman of the board of directors.

Our board of directors is divided into three classes, as follows:

  • Class I, which will consist of Ian T. Clark, William D. Lese and Daniel H. Miller whose terms will expire at our annual meeting of stockholders to be held in 2012;
  • Class II, which will consist of Michael V. Arbige, Jerry Fiddler and Ann Mather whose terms will expire at our annual meeting of stockholders to be held in 2013; and
  • Class III, which will consist of Jonathan S. Wolfson and Harrison F. Dillon whose terms will expire at our annual meeting of stockholders to be held in 2014.